Lowest Price Guaranteed
Pages
318
Last Updated
September 2026
View Count
31765
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Immune Checkpoint Inhibitors
6.2.1. Key Characteristics Immune Checkpoint Inhibitors
6.2.2. Advantages of Immune Checkpoint Inhibitors
6.2.3. Challenges Associated with Immune Checkpoint Inhibitors
6.3. Future Perspective
7. REGULATORY SCENARIO
8. COMPREHENSIVE DATABASE OF LEADING PLAYERS
9. COMPETITIVE LANDSCAPE
9.1. Chapter Overview
9.2. Immune Checkpoint Inhibitors: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Immune Checkpoint Inhibitors Market: Overall Market Landscape
9.2.4.1. Analysis by Type of Immune Checkpoint Inhibitors Proteins
9.2.4.2. Analysis by Target Disease Indication
9.2.4.3. Analysis by Type of Therapeutic Modality
9.2.4.4. Analysis by Route of Administration
10. COMPETITIVE COMPETITIVENESS ANALYSIS
11. STARTUP ECOSYSTEM IN THE IMMUNE CHECKPOINT INHIBITORS MARKET
11.1. Immune Checkpoint Inhibitors: Market Landscape of Startups
11.1.1. Analysis by Year of Establishment
11.1.2. Analysis by Company Size
11.1.3. Analysis by Company Size and Year of Establishment
11.1.4. Analysis by Location of Headquarters
11.1.5. Analysis by Company Size and Location of Headquarters
11.1.6. Analysis by Ownership Structure
11.2. Key Findings
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. AstraZeneca (UK)
12.2.1. Company Overview
12.2.2. Company Mission
12.2.3. Company Footprint
12.2.4. Management Team
12.2.5. Contact Details
12.2.6. Financial Performance
12.2.7. Operating Business Segments
12.2.8. Product Portfolio
12.2.9. MOAT Analysis
12.2.10. Recent Developments and Future Outlook
* similar detail is presented for other below mentioned companies based on information in the public domain
12.3. BeiGene (China)
12.4. Bristol-Myers Squibb (US)
12.5. Eli Lilly (US)
12.6. GlaxoSmithKline (UK)
12.7. Immunetep (Australia)
12.8. Merck (US)
12.9. Novartis (US)
12.10. Regeneron Pharmaceuticals (US)
12.11. Roche (Switzerland)
12.12. Sanofi (France)
12.13. Shanghai Jhunsi Biosciences (China)
13. PORTER'S FIVE FORCES ANALYSIS
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Immune Checkpoint Inhibitors: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Partner
14.3.5. Analysis by Location of Headquarters of Partner
14.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Regional Analysis
15. FUNDING AND INVESTMENTS ANALYSIS
15.1. Funding Models
15.2. Immune Checkpoint Inhibitors: Funding and Investments
15.2.1. Analysis by Year of Funding
15.2.2. Analysis of Funding Instances by Type of Funding
15.2.3. Analysis of Funding Instances by Year and Type of Funding
15.2.4. Analysis of Amount Invested by Type of Funding
15.2.5. Analysis of Funding Instances by Country
15.2.6. Most Active Players: Analysis by Amount Raised
15.3. Summary and Key Takeaways
16. CLINICAL TRIAL ANALYSIS
16.1. Analysis Methodology and Key Parameters
16.2. Intravenous Immunoglobulin: Clinical Trial Analysis
16.2.1. Analysis by Trial Status
16.2.2. Analysis by Trial Registration Year
16.2.3. Analysis by Type of Sponsor / Collaborator
16.2.4. Analysis by Type of Study Design
16.2.5. Analysis by Registration Year and Type of Study
16.2.6. Analysis by Patient Enrollment
16.2.7. Year-wise Trend of Completed and Recruiting Trials
16.2.8. Analysis by Age Category
16.2.9. Word Cloud of Study Titles
16.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
16.2.11. Most Active Non- Industry Players: Analysis by Number of Registered Trials
16.2.12. Analysis by Trial Location
16.2.13. Analysis by Trial Status and Geography
17. BIG PHARMA ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Analysis by Year of Initiative
17.3.1. Analysis by Type of Initiative
17.3.2. Analysis by Type of Collaboration
17.3.3. Analysis by Focus Area
17.3.4. Most Active Big Pharma Players: Analysis by Number of Initiatives
18. ACADEMIC GRANTS ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
18.3.1. Analysis by Year of Grant Award
18.3.2. Analysis by Amount Awarded
18.3.3. Analysis by Administering Institute Center
18.3.4. Analysis by Funding Institute Center
18.3.5. Analysis by Support Period
18.3.6. Analysis by Funding Institute Center and Support Period
18.3.7. Analysis by Type of Grant Application
18.3.8. Analysis by Purpose of Grant Award
18.3.9. Analysis by Grant Mechanism
18.3.10. Word Cloud: Emerging Focus Areas
18.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
18.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
18.3.13. Analysis by Study Section Involved
18.3.14. Popular NIH Departments: Analysis by Number of Grants
18.3.15. Analysis by Types of Recipient Organizations
19. TARGET COMPETITIVENESS ANALYSIS
19.1. Chapter Overview
19.2. Scope and Methodology
19.3. Key Parameters
19.4. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
19.4.1. Four-Dimensional Bubble Analysis
19.4.2 Five-Dimensional Spider Web Analysis
20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Trends Disruption Impacting Market
20.4. Demand Side Trends
20.5. Supply Side Trends
20.6. Global Immune Checkpoint Inhibitors Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Multivariate Scenario Analysis
20.7.1. Conservative Scenario
20.7.2. Optimistic Scenario
20.8. Investment Feasibility Index
20.9. Key Market Segmentations
21. MARKET OPPORTUNITIES BASED ON TYPE OF IMMUNE CHECKPOINT INHIBITORS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Immune Checkpoint Inhibitors Market for PD-1: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Immune Checkpoint Inhibitors Market for PD-L1: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. Immune Checkpoint Inhibitors Market for CTLA-4: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.9. Immune Checkpoint Inhibitors Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.10. Data Triangulation and Validation
21.10.1. Secondary Sources
21.10.2. Primary Sources
21.10.3. Statistical Modeling
22. MARKET OPPORTUNITIES BASED ON TARGET DISEASE INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Immune Checkpoint Inhibitors Market for Lung Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Immune Checkpoint Inhibitors Market for Breast Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.8. Immune Checkpoint Inhibitors Market for Bladder Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.9. Immune Checkpoint Inhibitors Market for Cervical Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.10. Immune Checkpoint Inhibitors Market for Colorectal Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.11. Immune Checkpoint Inhibitors Market for Melanoma: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.12. Immune Checkpoint Inhibitors Market for Hodgkin Lymphoma: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.13. Immune Checkpoint Inhibitors Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.14. Data Triangulation and Validation
22.14.1. Secondary Sources
22.14.2. Primary Sources
22.14.3. Statistical Modeling
23. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPEUTIC MODALITY
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. Immune Checkpoint Inhibitors Market for Antibody Fragments: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Immune Checkpoint Inhibitors Market for Monoclonal Antibodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.8. Immune Checkpoint Inhibitors Market for Small Molecules: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.9. Immune Checkpoint Inhibitors Market for Other Modalities: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.10. Data Triangulation and Validation
23.10.1. Secondary Sources
23.10.2. Primary Sources
23.10.3. Statistical Modeling
24. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix
24.6. Immune Checkpoint Inhibitors Market for Intravenous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.7. Immune Checkpoint Inhibitors Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.8. Immune Checkpoint Inhibitors Market for Intracellular: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.9. Immune Checkpoint Inhibitors Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.10. Data Triangulation and Validation
24.10.1. Secondary Sources
24.10.2. Primary Sources
24.10.3. Statistical Modeling
25. MARKET OPPORTUNITIES FOR IMMUNE CHECKPOINT INHIBITORS IN NORTH AMERICA
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix
25.6. Immune Checkpoint Inhibitors Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. Immune Checkpoint Inhibitors Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.2. Immune Checkpoint Inhibitors Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. Immune Checkpoint Inhibitors Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.7. Data Triangulation and Validation
26. MARKET OPPORTUNITIES FOR IMMUNE CHECKPOINT INHIBITORS IN EUROPE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix
26.6. Immune Checkpoint Inhibitors Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. Immune Checkpoint Inhibitors Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. Immune Checkpoint Inhibitors Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. Immune Checkpoint Inhibitors Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.4. Immune Checkpoint Inhibitors Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.5. Immune Checkpoint Inhibitors Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.6. Immune Checkpoint Inhibitors Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.7. Data Triangulation and Validation
27. MARKET OPPORTUNITIES FOR IMMUNE CHECKPOINT INHIBITORS IN ASIA-PACIFIC
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Revenue Shift Analysis
27.4. Market Movement Analysis
27.5. Penetration-Growth (P-G) Matrix
27.6. Immune Checkpoint Inhibitors Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.1. Immune Checkpoint Inhibitors Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.2. Immune Checkpoint Inhibitors Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.3. Immune Checkpoint Inhibitors Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.4. Immune Checkpoint Inhibitors Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.5. Immune Checkpoint Inhibitors Market in New Zealand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.6. Immune Checkpoint Inhibitors Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.7. Data Triangulation and Validation
28. MARKET OPPORTUNITIES FOR IMMUNE CHECKPOINT INHIBITORS IN MIDDLE EAST AND AFRICA (MEA)
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Revenue Shift Analysis
28.4. Market Movement Analysis
28.5. Penetration-Growth (P-G) Matrix
28.6. Immune Checkpoint Inhibitors Market in Middle East and Africa (MEA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.1. Immune Checkpoint Inhibitors Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.2. Immune Checkpoint Inhibitors Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.3. Immune Checkpoint Inhibitors Market in Iraq: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.4. Immune Checkpoint Inhibitors Market in Israel: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.5. Immune Checkpoint Inhibitors Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.6. Immune Checkpoint Inhibitors Market in South Africa: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.7. Immune Checkpoint Inhibitors Market in United Arab Emirates: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.7. Data Triangulation and Validation
29. MARKET OPPORTUNITIES FOR IMMUNE CHECKPOINT INHIBITORS IN LATIN AMERICA
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Revenue Shift Analysis
29.4. Market Movement Analysis
29.5. Penetration-Growth (P-G) Matrix
29.6. Immune Checkpoint Inhibitors Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.6.1. Immune Checkpoint Inhibitors Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.6.2. Immune Checkpoint Inhibitors Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.7. Data Triangulation and Validation
30 ADJACENT MARKET ANALYSIS
31. KEY WINNING STRATEGIES
32. SWOT ANALYSIS
33. ROOTS STRATEGIC RECOMMENDATIONS
34. INSIGHTS FROM PRIMARY RESEARCH
35. REPORT CONCLUSION
36. TABULATED DATA
37. LIST OF COMPANIES AND ORGANIZATIONS
38. CUSTOMIZATION OPPORTUNITIES
39. ROOTS SUBSCRIPTION SERVICES
40 AUTHOR DETAILS